Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Tumor-associated fibroblasts are key regulators of tumorigenesis. In contrast to tumor cells, which are genetically unstable and mutate frequently, the presence of genetically more stable fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer immunotherapy. These cells are also the primary source of collagen type I, which contributes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in regulating tumor sensitivity to a variety of chemotherapies. To specifically kill tumor-associated fibroblasts, we constructed an oral DNA vaccine targeting fibroblast activation protein (FAP), which is specifically overexpressed by fibroblasts in the tumor stroma. Through CD8+ T cell-mediated killing of tumor-associated fibroblasts, our vaccine successfully suppressed primary tumor cell growth and metastasis of multidrug-resistant murine colon and breast carcinoma. Furthermore, tumor tissue of FAP-vaccinated mice revealed markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs. Most importantly, pFap-vaccinated mice treated with chemotherapy showed a 3-fold prolongation in lifespan and marked suppression of tumor growth, with 50% of the animals completely rejecting a tumor cell challenge. This strategy opens a new venue for the combination of immuno- and chemotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, depleting fibroblast activation protein (FAP)+ CAFs via a FAP vaccine decreases collagen density and improves chemoresistance in mouse models [99].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
The myofibroblast in wound healing and fibrocontractive diseases
Gabbiani, G. (2003) · The Journal of Pathology · doi:10.1002/path.1427 · Cited by 1,630
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Stromal Effects on Mammary Gland Development and Breast Cancer
Wiseman, B. S., & Werb, Z. (2002) · Science · doi:10.1126/science.1067431 · Cited by 923
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Cited by
Items 301–400 of 648
Ohshio, Y., Hanaoka, J., Kontani, K., & Teramoto, K. (2014) · Scandinavian Journal of Immunology · doi:10.1111/sji.12242 · Cited by 48
Li, W., Little, N., Park, J., Foster, C. A., Chen, J., & Lu, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00455 · Cited by 47
“proved that the FAP DNA vaccine can effectively eliminate TAFs and inhibit the growth of primary tumors of colon and breast cancer in non-metastatic mice[94].”
Jiang, G., Xie, W., Wang, H., Du, J., Bai-ping, W., Xu, W., Liu, H., Xiao, P., Liu, Z.-G., Li, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4577 · Cited by 49
“Targeting FAPα genetically or with vaccines or pharmacological agents has been shown to impair tumor progression in several preclinical cancer models [26, 27].”
BackgroundSK4 channels modulate Ca2+ signalling and cell cycle progression in murine breast cancer
Steudel, F. A., Mohr, C. J., Stegen, B., Nguyen, H. Y., Barnert, A., Steinle, M., Beer‐Hammer, S., Koch, P., Lo, W., Schroth, W., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12087 · Cited by 50
“4), possibly due to an impaired immune and/or stromal cell response, which results in a tumour progression-promoting microenvironment (Jinushi et al., 2011; Loeffler et al., 2006; Wiseman and Werb, 2002) that counteracts the loss of the oncogenic SK4 functions in the tumour cells.”
BackgroundDana, P., Thumrongsiri, N., Tanyapanyachon, P., Chonniyom, W., Punnakitikashem, P., & Saengkrit, N. (2022) · Nanomaterials · doi:10.3390/nano13010107 · Cited by 53
Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts
Koon, H. W., Cheng, M., Ho, S., Yoo, J. H., Bakirtzi, K., Tran, D. H., Su, B., Tran, D., Ichikawa, R., & Kubota, Y. (2014) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s70906 · Cited by 54
Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment
Peng, Y., Bariwal, J. B., Kumar, V., Tan, C., & Mahato, R. I. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900136 · Cited by 46
Therapeutic antitumor potential of endoglin-based DNA vaccine combined with immunomodulatory agents
Jarosz–Biej, M., Jazowiecka-Rakus, J., Cichoń, T., Głowala‐Kosińska, M., Smolarczyk, R., Smagur, A., Malina, S., Sochanik, A., & Szala, S. (2012) · Gene Therapy · doi:10.1038/gt.2012.28 · Cited by 49
Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology
Valcz, G., Sipos, F., Tulassay, Z., Molnar, B., & Yagi, Y. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202561 · Cited by 39
Tumor stroma and chemokines control T-cell migration into melanoma following Temozolomide treatment
Tan, K. W., Evrard, M., Tham, M., Hong, M. L. W., Huang, C. W., Kato, M., Prévost‐Blondel, A., Donnadieu, E., Ng, L. G., & Abastado, J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.978709 · Cited by 46
“Although the dense stroma in skin tumors can act as a biophysical barrier to restrict access of T cells, our previous data and others suggest that the tumor stroma does not constitute an absolute barrier to T-cell recruitment, and that such structural constraints may be overcome by either the increased expression of T…”
ResultThe good and bad of targeting cancer-associated extracellular matrix
Sangaletti, S., Chiodoni, C., Tripodo, C., & Colombo, M. P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.06.003 · Cited by 48
“Indeed there are preclinical data, obtained with mouse models, showing that FAP-vaccinated mice had markedly decreased collagen type I expression and increased uptake of chemotherapeutic drugs [54].”
BackgroundTherapeutic modulators of hepatic stellate cells for hepatocellular carcinoma
Ruan, Q., Wang, H., Burke, L. J., Bridle, K. R., Li, X., Zhao, C., Crawford, D. H., Roberts, M. S., & Liang, X. (2020) · International Journal of Cancer · doi:10.1002/ijc.32899 · Cited by 48
“FAP-vaccinated mice showed a decrease of collagen type I expression, 70% greater uptake of chemotherapeutic drugs, suppression of tumor growth as well as a threefold prolongation in lifespan.(92) Hence, stimulation of a specific immune response to activated HSCs in the TME is a promising new approach in HCC treatment.”
BackgroundMarcucci, F., Bellone, M., Rumio, C., & Corti, A. (2013) · mAbs · doi:10.4161/mabs.22775 · Cited by 46
Leveraging microenvironmental synthetic lethalities to treat cancer
Metcalf, K. J., Alazzeh, A., Werb, Z., & Weaver, V. M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143765 · Cited by 42
“For example, depletion of FAP+ CAFs using a FAP vaccine decreases collagen density in tumors and improves response to doxorubicin in mice (135).”
MethodDharani, S., Cho, H., Postigo, J., Juillerat, A., Valton, J., Duchateau, P. N., Poirot, L., & Das, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.018 · Cited by 46
Fra-1 Promotes Breast Cancer Chemosensitivity by Driving Cancer Stem Cells from Dormancy
Lü, D., Chen, S., Tan, X., Li, N., Liu, C., Li, Z., Liu, Z., Stupack, D. G., Reisfeld, R. A., & Xiang, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2536 · Cited by 42
Knipper, K., Lyu, S. I., Quaas, A., Bruns, C. J., & Schmidt, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713482 · Cited by 46
“In the mice studies conducted, no indications of impaired wound healing or autoimmune reactions were observed [133,134].”
BackgroundFang, J., Hu, B., Li, S., Zhang, C., Liu, Y., & Wang, P. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.7 · Cited by 43
Geng, F., Bao, X., Dong, L., Guo, Q., Guo, J., Xie, Y., Zhou, Y., Yu, B., Wu, H., Wu, J., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1747350 · Cited by 45
Kennedy, A., Dong, H., Chen, D., & Chen, W. (2008) · International Journal of Cancer · doi:10.1002/ijc.23871 · Cited by 41
Unsworth, A., Anderson, R. L., & Britt, K. L. (2014) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-014-9326-8 · Cited by 41
“In several preclinical studies, targeting FAP genetically or with vaccines or pharmacological agents, resulted in impaired tumor progression inmice [143–145,107,146–148].”
BackgroundDual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives
Toledo, B., Picon‐Ruiz, M., Marchal, J. A., & Perán, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415576 · Cited by 42
“Oral DNA vaccines against FAPα that have demonstrated efficacy in mice models of breast or colon carcinomas are also being tested [7], along with other immunotoxins targeting FAPα such FAP-PE38 [291] (Figure 6).”
BackgroundFarrow, B. J., Berger, D. H., & Rowley, D. R. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.03.040 · Cited by 45
“Targeting elements of the tumor microenvironment is a successful strategy for increasing the effectiveness of therapy in other cancers [22, 23].”
BackgroundCrosstalk between fibroblasts and T cells in immune networks
Lee, B., Lee, S., & Shin, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1103823 · Cited by 43
Xu, J., Lü, Y., Qiu, S., Chen, Z., & Fan, Z. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.02.054 · Cited by 40
Stromal biomarkers in breast cancer development and progression
Rudnick, J. A., & Kuperwasser, C. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9499-8 · Cited by 42
“Vaccinating mice with an oral DNA vaccine targeting FAP significantly reduces mammary tumor development through cytotoxic T cell mediated elimination of CAFs [30].”
BackgroundA Digest on the Role of the Tumor Microenvironment in Gastrointestinal Cancers
Augsten, M., Hägglöf, C., Peña, C., & Östman, A. (2010) · Cancer Microenvironment · doi:10.1007/s12307-010-0040-9 · Cited by 40
“[127].”
Kalaei, Z., Manafi‐Farid, R., Rashidi, B., Kiani, F. K., Zarei, A., Fathi, M., & Jadidi‐Niaragh, F. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01151-y · Cited by 37
“Moreover, when chemotherapy drugs were applied in FAP-vaccinated mice, the absorption of chemotherapeutic drugs became 70% higher, tumor growth was strongly suppressed, and the lifespan got much longer [16].”
BackgroundTumor microenvironment in invasive lobular carcinoma: possible therapeutic targets
Nakagawa, S., Miki, Y., Miyashita, M., Hata, S., Takahashi, Y., Rai, Y., Sagara, Y., Ohi, Y., Hirakawa, H., Tamaki, K., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3668-9 · Cited by 37
Gu, J., Li, Z., Zhou, J., Sun, Z., & Bai, C. (2019) · Oncology Letters · doi:10.3892/ol.2019.10474 · Cited by 44
Formation and regulation of the cancer stem cell niche
Takakura, N. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02270.x · Cited by 39
Cyclic Multiplexed-Immunofluorescence (cmIF), a Highly Multiplexed Method for Single-Cell Analysis
Eng, J. R., Thibault, G., Luoh, S., Gray, J. W., Chang, Y. H., & Chin, K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_24 · Cited by 37
The Tumor Microenvironment: Part 1
Leibovici, J., Itzhaki, O., Huszar, M., & Sinai, J. (2011) · Immunotherapy · doi:10.2217/imt.11.111 · Cited by 39
Immune Resistance Mechanisms and the Road to Personalized Immunotherapy
Piper, M., Kluger, H. M., Ruppin, E., & Hu‐Lieskovan, S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390290 · Cited by 43
Zhang, X., Zhu, R., Yu, D., Wang, J., Yan, Y., & Xu, K. (2023) · Cell Proliferation · doi:10.1111/cpr.13592 · Cited by 37
“123”
Fibroblasts in Orchestrating Colorectal Tumorigenesis and Progression
Abudukelimu, S., de Miranda, N. F. C. C., & Hawinkels, L. J. A. C. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.01.013 · Cited by 36
“…of FAP þ CAFs using a DNA vaccine that induces CD8 T-cell killing of CAFs has been shown to inhibit tumor progression in a murine model for CRC. 49 Although promising preclinical data on FAP targeting, clinical trials evaluating monoclonal antibodies against FAP have not shown the expected ef…”
BackgroundInfluentialIelpo, S., Barberini, F., Moghaddam, F. D., Pesce, S., Cencioni, C., Spallotta, F., Ninno, A. D., Businaro, L., Marcenaro, E., Bei, R., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102843 · Cited by 36
Cadamuro, M., Morton, S. D., Strazzabosco, M., & Fabris, L. (2013) · PubMed · doi:10.3978/j.issn.2224-4778.2013.04.02 · Cited by 39
“org/tgc mice with mammary and colon carcinomas (112).”
BackgroundKim, D. K., Kim, E. K., Jung, D., & Kim, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214553 · Cited by 37
Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity
Bota‐Rabassedas, N., Banerjee, P., Niu, Y., Cao, W., Luo, J., Xi, Y., Tan, X., Sheng, K., Ahn, Y., Lee, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109009 · Cited by 34
Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond
Wei, D., Qi, J., Hamblin, M. R., Wen, X., Jiang, X. L., & Yang, H. (2022) · Theranostics · doi:10.7150/thno.74820 · Cited by 37
State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez, B., Rivas-Pardo, B., del Moral, M. G., Subiza, J. L., & Martínez-Naves, E. (2024) · Cells · doi:10.3390/cells13090725 · Cited by 40
“FAP-directed CAR-T cells have been developed to target CAFs in several solid tumors, including mesothelioma, lung cancer, and pancreatic cancer, demonstrating antitumor activity in preclinical models [36–38].”
BackgroundNuclear Receptors as Modulators of the Tumor Microenvironment
Sherman, M. H., Downes, M., & Evans, R. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0528 · Cited by 39
“Similarly, ablation of cancer-associated fibroblasts in several mouse models of cancer, via fibroblast activation protein-targeted vaccination (43) or genetic engineering (44), has been shown to reduce”
BackgroundCosta, D., Venè, R., Benelli, R., Romairone, E., Scabini, S., Catellani, S., Rebesco, B., Mastracci, L., Grillo, F., Minghelli, S., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01150 · Cited by 34
Nano-baicalein facilitates chemotherapy in breast cancer by targeting tumor microenvironment
Zheng, F., Luo, Y., Liu, Y., Gao, Y., Chen, W., & Wei, K. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122778 · Cited by 34
Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics
Chen, X., Wu, Y., Jia, S., & Zhao, M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08997-1 · Cited by 39
“Consensus DNA vaccines targeting FAP have also demonstrated potential in modifying the tissue microenvironment and alleviating breast cancer progression [156, 157].”
Stromal disruption facilitating invasion of a ‘nano-arsenal’ into the solid tumor
Fu, Y., Saraswat, A. L., Monpara, J. D., & Patel, K. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.015 · Cited by 33
Cancer‐associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?
Aden, D., Zaheer, S., Ahluwalia, H., & Ranga, S. (2023) · Cell Biology International · doi:10.1002/cbin.12004 · Cited by 33
Dissecting the Role of Bone Marrow Stromal Cells on Bone Metastases
Buenrostro, D., Park, S. I., & Sterling, J. A. R. (2014) · BioMed Research International · doi:10.1155/2014/875305 · Cited by 33
“One group found that CAF-induced resistance to tamoxifen could be reversed using metformin or arsenic trioxide [119].”
BackgroundZarodniuk, M., Steele, A., Lü, X., Li, J., & Datta, M. (2023) · npj Genomic Medicine · doi:10.1038/s41525-023-00381-w · Cited by 35
“Clusters 3, 4, and 5 predominantly contained meningioma mesenchymal subtypes together with meningeal GBM fi broblasts; cluster 0 consisted almost entirely of pericytes and smooth muscle cells.”
Sun, Y., Wang, R., Qiao, M., Yan-chun, X., Guan, W., & Wang, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26433 · Cited by 39
Baum, P., Müller, D., Rüger, R., & Kontermann, R. E. (2007) · Journal of drug targeting · doi:10.1080/10611860701453034 · Cited by 33
“In addition, a recent study showed that intratumoral drug uptake can be increased by vaccination with an oral DNA vaccine targeting FAP, which induces CD8þT cell-mediated killing of tumor-associated fibroblasts (Loeffler et al. 2006).”
BackgroundIn situ antitumor vaccination: Targeting the tumor microenvironment
Li, H., Yu, J., Wu, Y., Shao, B., & Wei, X. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29551 · Cited by 35
Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets
Li, Y., Liu, Q., Jing, X., Wang, Y., Jia, X., Yang, X., & Chen, K. (2025) · MedComm · doi:10.1002/mco2.70292 · Cited by 45
“In animal models, these vaccines have demonstrated strong CD8 + T cell activation, high targeting specificity, and promising tumor-suppressive effects [480–482].”
Dong, Y., Yang, Y., Wei, Y., Gao, Y., Jiang, W., Wang, G., & Wang, D. (2020) · Process Biochemistry · doi:10.1016/j.procbio.2020.05.011 · Cited by 31
Yao, M., Yu, E., Staggs, V. S., Fan, F., & Cheng, N. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.78 · Cited by 31
Qiu, X., Geng, F., Zhang, F.-F., Liu, C., Xu, P., Lu, Z.-Z., Xie, Y., Sun, B., Wu, H., Yu, B., et al. (2016) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2016.1269337 · Cited by 31
Extracellular Matrix Stiffness Exists in a Feedback Loop that Drives Tumor Progression
Simi, A. K., Pang, M.-F., & Nelson, C. M. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-95294-9_4 · Cited by 35
Metabolic and immune crosstalk between cancer-associated fibroblasts and pancreatic cancer cells
Zhang, Q., Cao, Z., Yan, S., Chen, B., Wu, H., Cao, H., Chen, L., & Liu, Z. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07164-0 · Cited by 37
“FAP-targeted therapies that deplete CAFs can enhance anti-cancer immune responses mediated by high levels of certain inflammatory mediators (such as IFN-γ and TNF-α), promoting CD8 + T cell cytotoxicity and metabolism while reducing pro-proliferative stroma in the TME [123, 124].”
You, E., Huh, Y. H., Kwon, A., Kim, S., Chae, I. H., Lee, O.-J., Ryu, J.-H., Park, M. H., Kim, G., Lee, J. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0657 · Cited by 30
Celli, J. P. (2012) · Israel Journal of Chemistry · doi:10.1002/ijch.201200013 · Cited by 30
Huang, C., Suen, C., Lin, C., Chien, C., Lee, H.-Y., Chung, K., Tsai, T., Jiaang, W.-T., Hwang, M., & Chen, X. (2011) · The Journal of Biochemistry · doi:10.1093/jb/mvr017 · Cited by 31
Strategies to improve outcomes in esophageal adenocarcinoma
Cowie, A., Noble, F., & Underwood, T. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.895668 · Cited by 30
“CAF have been immunotherapeutic targets through the use of fibroblast-activating protein vaccinations, prolonging survival when used in combination with chemotherapy in murine models of breast and colorectal cancer [84].”
BackgroundQiu, X., Zhang, F.-F., Geng, F., Liu, C., Wang, Y., Xu, P., Lu, Z.-Z., Xie, Y., Wu, H., Chen, Y., et al. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.08.006 · Cited by 30
Metabolic hijacking: A survival strategy cancer cells exploit?
Mitchell, M. I., & Engelbrecht, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.010 · Cited by 31
A T-cell engager-armed oncolytic vaccinia virus to target the tumor stroma
Song, X., Feng, Y., & Hong, B. (2017) · Cancer translational medicine · doi:10.4103/ctm.ctm_13_17 · Cited by 32
Not only tumor but also therapy heterogeneity
Garattini, S. K., Nerini, I. F., & D’Incalci, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx646 · Cited by 34
Geng, F., Guo, J., Guo, Q., Xie, Y., Dong, L., Zhou, Y., Liu, C., Yu, B., Wu, H., Wu, J., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.06.012 · Cited by 32
Gan, L., Lü, T., Lu, Y., Song, H., Zhang, J., Zhang, K., Lu, S., Wu, X., Nie, F., Di, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009111 · Cited by 34
Guo, P., Shang, W., Peng, L., Wang, L., Wang, H., Han, Z., Jiang, H., Tian, J., Wang, K., & Xu, W. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.036 · Cited by 29
Li, X., Chen, M., Lu, W., Tang, J., Deng, L., Wen, Q., Huang, M., Deng, R., Ye, G., Ye, W., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.013 · Cited by 29
Thiery, J. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00103 · Cited by 33
“For example, an oral DNA vaccine targeting FAP has successfully demonstrated its ability to induce CD8+ T cell-mediated killing of CAF and to suppress primary tumor cell growth and metastasis of colon and breast murine carcinoma [226].”
BackgroundDou, T., Li, J., Zhang, Y., Pei, W., Zhang, B., Wang, B., Wang, Y., & Jia, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1368687 · Cited by 33
Jeschke, J., Collignon, É., & Fuks, F. (2014) · FEBS Journal · doi:10.1111/febs.13125 · Cited by 30
Mhawech-Fauceglia, P. Y., Wang, D., Samrao, D., Kim, G., Lawrenson, K., Meneses, T., Liu, S., Yessaian, A. A., & Pejovic, T. B. (2013) · Cancer Microenvironment · doi:10.1007/s12307-013-0140-4 · Cited by 32
Zhou, L., YANG, K. Y., Wickett, R. R., Kadekaro, A. L., & Zhang, Y. (2016) · Tumor Biology · doi:10.1007/s13277-016-5293-6 · Cited by 31
Verhulst, E., Garnier, D., Meester, I. D., & Bauvois, B. (2022) · Cancers · doi:10.3390/cancers14030624 · Cited by 30
Song, X.-H., Yang, L., Zheng, X., Zhu, Q., Liao, X.-L., Liu, K., Zhang, W., Peng, Q., Zhu, Y., Zhao, L.-Y., et al. (2023) · MedComm · doi:10.1002/mco2.342 · Cited by 32
Role of Tumor Associated Fibroblasts in Human Liver Regeneration, Cirrhosis, and Cancer
Cesselli, D., Beltrami, A. P., Poz, A., Marzinotto, S., Comisso, E., Bergamin, N., Bourkoula, E., Pucer, A., Puppato, E., Toffoletto, B., et al. (2011) · International Journal of Hepatology · doi:10.4061/2011/120925 · Cited by 30
“Accordingly, it has been constructed an oral DNA vaccine targeting FAP able to suppress, in vaccinated animals, primary tumor cell growth and metastasis of multidrug-resistant murine colon and breast carcinoma [48].”
BackgroundVandsburger, M. H., Radoul, M., Addadi, Y., Mpofu, S., Cohen, B., Eilam, R., & Neeman, M. (2013) · Radiology · doi:10.1148/radiol.13122053 · Cited by 29
Stromal characteristics may hold the key to mammographic density: the evidence to date
Ironside, A. J., & Jones, J. L. (2016) · Oncotarget · doi:10.18632/oncotarget.6912 · Cited by 29
“Such strategies involve; the development of anti-FAP antibodies conjugated to cytotoxic drugs [92], utilising the enzymatic activity of FAP to activate pro-drugs in the vicinity of the tumour [93], and vaccines targeted against FAP [94].”
BackgroundWang, J., Delfarah, A., Gelbach, P. E., Fong, E. J., Macklin, P., Mumenthaler, S. M., Graham, N. A., & Finley, S. D. (2021) · Metabolic Engineering · doi:10.1016/j.ymben.2021.11.006 · Cited by 28
“, hyaluronan and collagen) by CAFs has been found to affect drug penetration (Flach et al., 2011; Misra et al., 2003; Loeffler et al., 2006).”
BackgroundTan, X., Banerjee, P., Liu, X., Jiang, Y. L., Lee, S., Ahn, Y., Creighton, C. J., & Kurie, J. M. (2021) · JCI Insight · doi:10.1172/jci.insight.153948 · Cited by 30
“Although fibroblasts are generally considered to be the primary source of intratumoral collagen (28), tumor cells are emerging as an important source of collagen deposition (29).”
Dai, L., Qin, Z., DeFee, M. R., Toole, B. P., Kirkwood, K. L., & Parsons, C. H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.12.019 · Cited by 27
“Direct targeting of TAF also reduces cancer progression in vivo and sensitizes tumors to chemotherapy [25], further justifying additional mechanistic studies to understand the role of TAF in cancer pathogenesis.”
BackgroundZhang, H., Liu, C., Zhang, F.-F., Geng, F., Qiu, X., Lu, Z.-Z., Xu, P., Xie, Y., Wu, H., Yu, B., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.04.045 · Cited by 27
Highlights of Strategies Targeting Fibroblasts for Novel Therapies for Rheumatoid Arthritis
Chu, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846300 · Cited by 30
Meng, M., Wang, W., Yan, J., Tan, J. Y., Liao, L., Shi, J., Wei, C., Xie, Y., Jin, X., Yang, L., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-4825-4 · Cited by 28
Chang, A., Hsu, E. J., Patel, J. N., Li, Y., Zhang, M., Iguchi, H., & Rogoff, H. A. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1242 · Cited by 26
“Consequently, research efforts have begun to focus not only on targeting the tumor, but also the TME (11, 12, 14), as therapies that perturb or alter the function of TME cells or the ECM may improve response and reduce tumor resistance to radiotherapy and chemotherapy (13, 15, 16).”
BackgroundHasebe, T. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.757305 · Cited by 28
“Our studies also clearly showed that the histological and biological characteristics of tumor--stromal fibroblasts are significant outcome predictor for patients with IDC who have received neoadjuvant therapy [52,60], and other investigators have also reported that tumor--stromal fibroblasts or tumor--stromal endothel…”
ResultHutchins, G. G. A., Treanor, D. E., Wright, A. I., Handley, K., Magill, L., Tinkler‐Hundal, E., Southward, K., Seymour, M., Kerr, D. J., Gray, R. G., et al. (2017) · Histopathology · doi:10.1111/his.13326 · Cited by 31
Almici, E., Arshakyan, M., Carrasco, J. L., Martínez, A., Ramírez, J., Enguita, A. B., Monsó, E., Montero, J., Samitier, J., & Alcaraz, J. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100155 · Cited by 28
Hu, C., Wang, Z., Zhai, L., Miling, Y., Shan, L., Chai, C., Liu, M., & Wang, L. (2012) · Oncology Letters · doi:10.3892/ol.2012.1023 · Cited by 29
“They also inhibit the effect of FAP in tumor tissues and significantly improve the tumor sensitivity to chemotherapy and survival rate of rats with cancer (21-23).”
Targeting the tumour stroma to increase efficacy of chemo- and radiotherapy
Chometon, G., & Jendrossek, V. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0317-y · Cited by 30
“Anti-FAP antibodies in hibited breast tumour growth as single drugs or in combination with doxorubicin [ 64 , 89].”
BackgroundInfluentialBoddupalli, A., & Bratlie, K. M. (2019) · Biomaterials Science · doi:10.1039/c8bm01535j · Cited by 26
Microengineered 3D Tumor Models for Anti-Cancer Drug Discovery in Female-Related Cancers
Amirghasemi, F., Adjei‐Sowah, E., Pockaj, B. A., & Nikkhah, M. (2021) · Annals of Biomedical Engineering · doi:10.1007/s10439-020-02704-9 · Cited by 27
Mesenchymal stem cells and cancer‐associated fibroblasts as a therapeutic strategy for breast cancer
Borzone, F. R., Giorello, M. B., Sanmartin, M. C., Yannarelli, G., Martinez, L. M., & Chasseing, N. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15861 · Cited by 26
Xu, S., Jiemy, W. F., Brouwer, E., Burgess, J. K., Heeringa, P., van der Geest, K. S. M., Alba-Rovira, R., Corbera‐Bellalta, M., Boots, A. M. H., Cid, M. C., et al. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103574 · Cited by 25
Inoue, M., Matsumoto, S., Saito, H., Tsujitani, S., & Ikeguchi, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23867 · Cited by 24
“constructed an oral DNA vaccine targeting fibroblast activation protein (FAP), which is specifically overexpressed by fibroblasts in the tumor stroma, and found that tumor tissue of FAP-vaccinated mice exhibited markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs.(21) T…”
BackgroundInfluentialIn Situ Drug Delivery to Breast Cancer-Associated Extracellular Matrix
Fleming, J. M., Yeyeodu, S. T., McLaughlin, A., Schuman, D., & Taylor, D. K. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00396 · Cited by 25
Mollah, F., & Varamini, P. (2021) · Biomedicines · doi:10.3390/biomedicines9121921 · Cited by 26
“BCAF generated type I collagen, which was shown to reduce chemotherapeutic drug uptake and decrease sensitivity to therapy [60].”
Background
Metadata
- Authors
- Loeffler, M.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Loeffler, M.
- ORCID
- Loeffler, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1955-1962
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1481657
- OpenAlex
- W2002689409
- Cited by
- 633
- References
- 51
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 41 · 2023: 58 · 2022: 33 · 2021: 56 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 32 · 2016: 39 · 2015: 46 · 2014: 33 · 2013: 33 · 2012: 28
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- National Cancer Institute (CA 83856, R01CA083856)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer-associated fibroblasts, fibroblast activation protein, oral DNA vaccine, type I collagen, tumor stroma, chemosensitization, multidrug resistance, colon cancer, breast cancer, metastasis, chemoimmunotherapy
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Female, Fibroblasts, Membrane Proteins, Mice, Inbred BALB C, Neoplasms, Endopeptidases, Recombinant Fusion Proteins, Serine Endopeptidases, Survival Rate, Gelatinases, CD8-Positive T-Lymphocytes, Vaccines, DNA, Cancer Vaccines, Collagen Type I, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.